Hanson Pharmaceuticals (03692): Amex® (ametinib mesylate tablets) was issued a drug registration certificate by the State Drug Administration for the fourth indication

Zhitongcaijing · 3d ago

Zhitong Finance App News, Hanson Pharmaceuticals (03692) announced that the Group's innovative drug, ametinib (ametinib mesylate tablets), has obtained a drug registration certificate issued by the China National Drug Administration (NMPA), and approved the addition of “for use in II-IIIB stage with epidermal growth factor receptor (“EGFR”) exon 19 deficiency or exon 21 (L858R) replacement mutation. Patients must be treated by doctors who have previously undergone resection surgery and be determined by doctors Indications for “receiving or not receiving adjuvant chemotherapy”. This is the fourth approved indication for Amelox®.